<DOC>
	<DOCNO>NCT00227708</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Chemotherapy drug may different effect old patient . PURPOSE : This phase II trial study well docetaxel work treat old patient locally advanced metastatic non-small cell lung cancer .</brief_summary>
	<brief_title>Docetaxel Treating Older Patients With Locally Advanced Metastatic Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine quality life old patient locally advanced metastatic non-small cell lung cancer treat docetaxel . Secondary - Determine response rate patient treat drug . - Determine overall survival progression-free survival patient treated drug . - Determine mood status autonomy activity patient treat drug . - Determine toxicity drug patient . OUTLINE : This multicenter study . Patients receive docetaxel IV twice week 1 . Treatment repeat every 2 week 6 course absence disease progression unacceptable toxicity . Quality life assess study therapy week 3-4 , 7-8 , 11-12 , 6 12 month completion study treatment . PROJECTED ACCRUAL : A total 58 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer , include adenocarcinoma , squamous cell carcinoma , large cell carcinoma , combination histology Stage IIIB ( i.e. , pleural T4 ) disease Stage IV disease Recurrent disease prior surgery radiotherapy allow provided disease area previously irradiate Measurable disease CT scan MRI No symptomatic brain metastasis Activity Daily Living Scale score ≥ 4 Instrumental Autonomy Daily Living Scale score ≥ 4 PATIENT CHARACTERISTICS : Age 70 Performance status Not specify Life expectancy More 3 month Hematopoietic Neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin &gt; 10 g/dL Hepatic Transaminases &lt; 1.5 time normal Bilirubin normal Alkaline phosphatase &lt; 2.5 time normal Prealbumin &gt; 1.5 mg/dL Renal Creatinine clearance &gt; 30 mL/min Cardiovascular No congestive heart failure No unstable angina pectoris No myocardial infarction within past year No uncontrolled hypertension No uncontrolled highrisk arrhythmias Gastrointestinal No active peptic ulcer No inflammatory bowel disease Neurologic No history dementia seizure would preclude give informed consent No peripheral neuropathy ≥ grade 2 No history significant neurologic disorder Immunologic No history hypersensitivity study drug drug formulate polysorbate 80 No active uncontrolled infection Other No history psychotic disorder No uncontrolled diabetes mellitus No absolute contraindication corticosteroid use No malignancy within past 5 year except basal cell skin cancer carcinoma situ cervix No geriatric depression scale score ≥ 12/15 No familial , social , geographical , psychological reason would preclude study follow PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy stage IIIB IV nonsmall cell lung cancer No concurrent chemotherapy Endocrine therapy No concurrent chronic treatment corticosteroid except lowdose ( i.e. , methylprednisolone ≤ 20 mg/day equivalent ) treatment initiate &gt; 6 month ago Radiotherapy See Disease Characteristics Surgery See Disease Characteristics Other More 30 day since prior active participation another therapeutic clinical trial No concurrent anticancer therapy No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>70 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
</DOC>